New drug B007 aims to tame pemphigus with fewer meds
NCT ID NCT06454357
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called B007 in 132 people with pemphigus, a serious blistering skin disease. The goal is to see if B007 can help patients achieve complete remission while using minimal other treatments. Participants receive injections of B007 at high or low doses, and researchers will track how well the disease is controlled and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- B007 (a drug given as a subcutaneous injection)
- What this could lead to
- If successful, B007 could offer a new treatment option that helps people with pemphigus achieve remission with less medication.
- What could go wrong
- This is an early combined phase II/III trial with only 132 participants, so results may not confirm effectiveness or safety. The drug may cause side effects or fail to outperform existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEMPHIGUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chengdu Second People's Hospital
RECRUITINGChengdu, China
Contact
-
Dermatology Hospital of Southern Medical University
RECRUITINGGuangzhou, China
Contact
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, China
Contact
-
Henan Provincial People's Hospital
RECRUITINGZhengzhou, China
Contact
-
Peking University First Hospital
RECRUITINGBeijing, China
Contact
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, China
Contact
-
Shandong First Medical University-Affiliated Skin Hospital
RECRUITINGJinan, China
Contact
-
The First Affiliated Hospital of Chongqing Medical University
RECRUITINGChongqing, China
Contact
-
The First Affiliated Hospital of Fujian Medical University
RECRUITINGFuzhou, China
Contact
-
The Second Xiangya Hospital of Central South University
RECRUITINGChangsha, China
Contact
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, China
Contact
-
West China Hospital, Sichuan University
RECRUITINGChengdu, China
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental CAR-T injection aims to tame autoimmune diseases
- New antibody treatment offers hope for rare blistering skin disease
- Scientists launch hunt for clues in autoimmune skin diseases
- Smart antibody monitoring could prevent pemphigus Flare-Ups
- New study to measure hidden toll of rare skin diseases on patients and families
- Rituximab shows promise for long-term control of rare blistering skin disease